Literature DB >> 21691385

Acquired von Willebrand syndrome in a 10-year-old girl with acute lymphoblastic leukaemia.

Isabel Dorn1, Ulrich Budde, Michael C Frühwald, Monika Pöppelmann, Ulrike Nowak-Göttl.   

Abstract

UNLABELLED: Following diagnosis of acute lymphoblastic leukaemia (ALL) in a 10-year-old girl, routine coagulation screening including von Willebrand factor antigen (VWF:Ag), ristocetin cofactor activity (VWF:RCo) and factor VIIIC (FVIII:C) detected no pathological findings. After the first HR2' element of the high-risk group of the ALL-BFM 2000 protocol, the patient demonstrated extensive bleeding symptoms and acquired von Willebrand syndrome was diagnosed. VWF:Ag (13%), VWF:RCo (13%) and FVIII:C (27%) were decreased. Multimer analysis showed a loss of large multimers and a loss in triplet structures. The observed pattern was thought to be typical for monoclonal IgG gammopathy; however, in this case, unexpectedly, biclonal IgM gammopathy (κ and λ) was detected. After treatment with intravenous immunoglobulin over 5 days, coagulation factors increased to normal levels. Although this effect was assumed to be at best only temporary, especially in a case of IgM gammopathy, no further bleeding symptoms have been observed. TRIAL REGISTRATION NUMBER: M208.

Entities:  

Year:  2009        PMID: 21691385      PMCID: PMC3027580          DOI: 10.1136/bcr.04.2009.1816

Source DB:  PubMed          Journal:  BMJ Case Rep        ISSN: 1757-790X


  14 in total

1.  Acquired von Willebrand's disease due to excessive fibrinolysis.

Authors:  J C Eikenboom; F J van der Meer; E Briët
Journal:  Br J Haematol       Date:  1992-08       Impact factor: 6.998

2.  Effectiveness of high-dose intravenous immunoglobulin in a case of acquired von Willebrand syndrome with chronic melena not responsive to desmopressin and factor VIII concentrate.

Authors:  G Castaman; A Tosetto; F Rodeghiero
Journal:  Am J Hematol       Date:  1992-10       Impact factor: 10.047

Review 3.  Immune-mediated etiology of acquired von Willebrand syndrome in systemic lupus erythematosus and in benign monoclonal gammopathy: therapeutic implications.

Authors:  Jan J Michiels; Zwi Berneman; Alain Gadisseur; Marc van der Planken; Wilfried Schroyens; Ulrich Budde; Huub H D M van Vliet
Journal:  Semin Thromb Hemost       Date:  2006-09       Impact factor: 4.180

Review 4.  Acquired von Willebrand syndrome: is it an extremely rare disorder or do we see only the tip of the iceberg?

Authors:  A B Federici
Journal:  J Thromb Haemost       Date:  2008-01-25       Impact factor: 5.824

5.  The use of high-dose intravenous gamma-globulin in acquired von Willebrand syndrome.

Authors:  B G Macik; D A Gabriel; G C White; K High; H Roberts
Journal:  Arch Pathol Lab Med       Date:  1988-02       Impact factor: 5.534

6.  Clinical significance of inhibitors in acquired von Willebrand syndrome.

Authors:  H Mohri; S Motomura; H Kanamori; M Matsuzaki; S Watanabe; A Maruta; F Kodama; T Okubo
Journal:  Blood       Date:  1998-05-15       Impact factor: 22.113

Review 7.  Acquired von Willebrand syndromes: clinical features, aetiology, pathophysiology, classification and management.

Authors:  J J Michiels; U Budde; M van der Planken; H H van Vliet; W Schroyens; Z Berneman
Journal:  Best Pract Res Clin Haematol       Date:  2001-06       Impact factor: 3.020

8.  Studies of the pathophysiology of acquired von Willebrand's disease in seven patients with lymphoproliferative disorders or benign monoclonal gammopathies.

Authors:  P M Mannucci; R Lombardi; R Bader; M H Horellou; G Finazzi; C Besana; J Conard; M Samama
Journal:  Blood       Date:  1984-09       Impact factor: 22.113

9.  Treatment of acquired von Willebrand syndrome in patients with monoclonal gammopathy of uncertain significance: comparison of three different therapeutic approaches.

Authors:  A B Federici; F Stabile; G Castaman; M T Canciani; P M Mannucci
Journal:  Blood       Date:  1998-10-15       Impact factor: 22.113

Review 10.  Acquired von Willebrand disease in Wilms' tumor patients.

Authors:  M J Coppes; S W Zandvoort; C R Sparling; A O Poon; S Weitzman; V S Blanchette
Journal:  J Clin Oncol       Date:  1992-03       Impact factor: 44.544

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.